Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date |
Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date |
Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date |
Paratracheal Middle Mediastinal Thymic Carcinomas.  |
Paratracheal Middle Mediastinal Thymic Carcinomas.  |
Paratracheal Middle Mediastinal Thymic Carcinomas.  |
The Annals of thoracic surgery, 110, 1, e39-e41 |
The Annals of thoracic surgery, 110, 1, e39-e41 |
The Annals of thoracic surgery, 110, 1, e39-e41 |
2020/07 |
有 |
英語 |
|
公開 |
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai |
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai |
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai |
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. |
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. |
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. |
Molecular cancer therapeutics, 19, 6, 1320-1327 |
Molecular cancer therapeutics, 19, 6, 1320-1327 |
Molecular cancer therapeutics, 19, 6, 1320-1327 |
2020/06 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai |
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. |
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. |
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. |
Anticancer research, 40, 5, 2981-2987 |
Anticancer research, 40, 5, 2981-2987 |
Anticancer research, 40, 5, 2981-2987 |
2020/05 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai |
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai |
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai |
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.  |
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.  |
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.  |
Cell death & disease, 11, 3, 177-177 |
Cell death & disease, 11, 3, 177-177 |
Cell death & disease, 11, 3, 177-177 |
2020/03/09 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM |
HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM |
HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM |
Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer |
Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer |
Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer |
In Vivo, 34, 2, 897-902 |
In Vivo, 34, 2, 897-902 |
In Vivo, 34, 2, 897-902 |
2020/03 |
有 |
|
研究論文(学術雑誌) |
公開 |
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo |
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo |
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo |
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.  |
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.  |
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.  |
JCI insight, 5, 2 |
JCI insight, 5, 2 |
JCI insight, 5, 2 |
2020/01/30 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.  |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.  |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.  |
Nature communications, 11, 1, 74-74 |
Nature communications, 11, 1, 74-74 |
Nature communications, 11, 1, 74-74 |
2020/01/03 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai |
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. |
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. |
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. |
Oncology, 98, 7, 460-467 |
Oncology, 98, 7, 460-467 |
Oncology, 98, 7, 460-467 |
2020 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.  |
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.  |
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.  |
Scientific reports, 9, 1, 17085-17085 |
Scientific reports, 9, 1, 17085-17085 |
Scientific reports, 9, 1, 17085-17085 |
2019/11/19 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim |
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim |
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. |
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. |
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. |
Molecular cancer research : MCR, 17, 1, 212-224 |
Molecular cancer research : MCR, 17, 1, 212-224 |
Molecular cancer research : MCR, 17, 1, 212-224 |
2019/01 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai |
Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai |
Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai |
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. |
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. |
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. |
Respiratory medicine, 146, 66-70 |
Respiratory medicine, 146, 66-70 |
Respiratory medicine, 146, 66-70 |
2019/01 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI |
HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI |
HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI |
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer |
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer |
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer |
In Vivo, 32, 6, 1587-1590 |
In Vivo, 32, 6, 1587-1590 |
In Vivo, 32, 6, 1587-1590 |
2018/11 |
有 |
|
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Masahiro Ooi, Young Hak Kim |
Hironori Yoshida, Masahiro Ooi, Young Hak Kim |
Hironori Yoshida, Masahiro Ooi, Young Hak Kim |
Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. |
Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. |
Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 |
2018/11 |
有 |
英語 |
|
公開 |
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai |
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai |
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai |
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.  |
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.  |
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.  |
Thoracic cancer, 9, 7, 847-855 |
Thoracic cancer, 9, 7, 847-855 |
Thoracic cancer, 9, 7, 847-855 |
2018/07 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai |
H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai |
H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai |
Nivolumab in non-small-cell lung cancer with EGFR mutation |
Nivolumab in non-small-cell lung cancer with EGFR mutation |
Nivolumab in non-small-cell lung cancer with EGFR mutation |
Annals of Oncology, 29, 3, 777-778 |
Annals of Oncology, 29, 3, 777-778 |
Annals of Oncology, 29, 3, 777-778 |
2018/03 |
有 |
|
研究論文(学術雑誌) |
公開 |
Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim |
Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim |
Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim |
Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. |
Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. |
Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. |
Molecular and clinical oncology, 7, 4, 677-680 |
Molecular and clinical oncology, 7, 4, 677-680 |
Molecular and clinical oncology, 7, 4, 677-680 |
2017/10 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim |
Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim |
Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim |
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.  |
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.  |
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.  |
Oncotarget, 8, 42, 71805-71816 |
Oncotarget, 8, 42, 71805-71816 |
Oncotarget, 8, 42, 71805-71816 |
2017/09/22 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim |
Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim |
Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim |
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. |
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. |
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. |
Molecular and clinical oncology, 7, 2, 295-297 |
Molecular and clinical oncology, 7, 2, 295-297 |
Molecular and clinical oncology, 7, 2, 295-297 |
2017/08 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai |
EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. |
EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. |
EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. |
Anticancer research, 37, 5, 2721-2725 |
Anticancer research, 37, 5, 2721-2725 |
Anticancer research, 37, 5, 2721-2725 |
2017/05 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim |
Hironori Yoshida, Young Hak Kim |
Hironori Yoshida, Young Hak Kim |
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. |
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. |
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 |
2017/05 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim |
Hironori Yoshida, Young Hak Kim |
Hironori Yoshida, Young Hak Kim |
Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. |
Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. |
Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. |
Annals of translational medicine, 5, 7, 165-165 |
Annals of translational medicine, 5, 7, 165-165 |
Annals of translational medicine, 5, 7, 165-165 |
2017/04 |
有 |
英語 |
|
公開 |
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim |
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.  |
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.  |
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.  |
Scientific reports, 7, 45124-45124 |
Scientific reports, 7, 45124-45124 |
Scientific reports, 7, 45124-45124 |
2017/03/23 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura |
Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura |
Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura |
Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. |
Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. |
Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. |
Scientific reports, 6, 30941-30941 |
Scientific reports, 6, 30941-30941 |
Scientific reports, 6, 30941-30941 |
2016/08/08 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima |
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima |
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. |
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. |
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. |
Molecular and clinical oncology, 5, 1, 213-215 |
Molecular and clinical oncology, 5, 1, 213-215 |
Molecular and clinical oncology, 5, 1, 213-215 |
2016/07 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima |
Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima |
Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima |
Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. |
Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. |
Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. |
Molecular and clinical oncology, 3, 2, 334-340 |
Molecular and clinical oncology, 3, 2, 334-340 |
Molecular and clinical oncology, 3, 2, 334-340 |
2015/03 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima |
Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima |
Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima |
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. |
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. |
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 |
2013/09 |
有 |
英語 |
研究論文(学術雑誌) |
公開 |
Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. |
Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. |
Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. |
Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports |
Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports |
Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports |
Respiration and Circulation, 60, 11 |
Respiration and Circulation, 60, 11 |
Respiration and Circulation, 60, 11 |
2012 |
有 |
|
研究論文(学術雑誌) |
公開 |